New Science-Based Teaching Methodology from MEDNIVA Optimizes Global Healthcare Industry Education Efforts
- MEDNIVA is an exclusive licensee of Duke-NUS Medical School's patent-pending learning methods leveraging cognitive science to provide highly customized learning solutions for the global healthcare industry
- This learning methodology, InteLearn™, provides value to the healthcare industry by offsetting inefficient traditional investments while improving healthcare outcomes for both professionals and patients
- Validated by a top ten multinational pharmaceutical company, results showed a 145% increase in learners rating themselves as experts on content knowledge and 100% saying they were satisfied and would recommend MEDNIVA to colleagues
SINGAPORE and DURHAM, N.C., May 11, 2016 /PRNewswire/ -- MEDNIVA, an exclusive licensee of Duke-NUS Medical School, launched a new science-based method of learning to the global healthcare industry, which has been proven to be more effective than traditional education practices and can dramatically transform the way the industry educates its stakeholders.
InteLearn™ is an exclusive patent-pending teaching methodology leveraging cognitive science with active learning methods such as pre-test priming, peer learning, and recall. InteLearn™ has been shown to promote sustained learning and increase retention as compared to traditional passive learning techniques.
"Most adults have attention spans of about six to ten minutes, meaning they can forget up to 80% of a traditional one hour lecture," said Dr. Ranga Krishnan, academic advisor and co-founder of MEDNIVA. "Cognitive science has found that customized testing is 40% more effective than re-reading and other passive methods because it helps reinforce the information for better recall in the future. These and many other insights into how the human brain learns form the basis of InteLearn™."
InteLearn™ was recently validated by a large group of senior medical and commercial leaders at a top ten multinational pharmaceutical company with a highly customized, in-depth engagement with MEDNIVA. Results showed a 145% increase in learners who rated themselves as experts on the content after the MEDNIVA engagement. Additionally, 100% of participants said they were satisfied and would recommend MEDNIVA.
"Results were phenomenal, and participants were significantly more knowledgeable, credible, and persuasive after the MEDNIVA engagement. This truly demonstrates the benefits of science-led learning for a science-led industry," said Dr. Neil MacIntyre, pulmonologist and professor of medicine at Duke University Medical Center in Durham, North Carolina, USA, who was actively involved in this engagement.
"Duke-NUS Medical School is proud to support the launch of MEDNIVA and bring to the global healthcare industry what has worked so well with our medical students," said Dr. Thomas Coffman, dean of Duke-NUS Medical School in Singapore. The MEDNIVA teaching methodology, InteLearn™, was derived from the basis of teaching at both Duke-NUS Medical School (Singapore) and Duke University School of Medicine (USA).
An engagement with MEDNIVA is highly customized for both internal and external stakeholders, such as the salesforce, marketing teams, medical directors, physicians, pharmacists, nurses, and payers. The content is customized across multiple therapeutic areas with renowned faculty from Duke University and other leading global institutions to meet specific learning objectives. Live sessions include individual and team tests, case studies, active discussions, and simulations. There are no traditional lectures in an engagement with MEDNIVA. MEDNIVA also offers different levels of academically branded certification for successful learners.
"Healthcare companies are already spending heavily on educating their stakeholders, yet most of those investments are highly inefficient and do not deliver optimal learning outcomes. It's akin to education malpractice," said Sumeet Sud, chief executive officer and co-founder of MEDNIVA. "MEDNIVA offers a unique alternative to traditional marketing, sales, and medical education investments. We are confident that our patent-pending learning solution will disrupt education in the healthcare industry and optimize industry investments, while improving healthcare outcomes for both professionals and patients."
About MEDNIVA
MEDNIVA provides highly customized learning solutions to the global healthcare industry. With exclusive access to InteLearn™, the patent-pending learning methods leveraging cognitive science, and form the basis of learning at Duke-NUS Medical School (Singapore) and Duke University School of Medicine (USA), MEDNIVA creates value for the industry leading to better physician and patient outcomes.
To learn more about MEDNIVA, please visit: http://www.medniva.com/
About InteLearn™
InteLearn™, licensed exclusively from Duke-NUS Medical School to MEDNIVA for the global healthcare industry, is a patent-pending learning methodology applying cognitive science to optimize learning. InteLearn™ applies multiple proven learning techniques, such as pre-test priming, peer learning, and recall testing to optimize sustained learning in customized environments.
To learn more about InteLearn™, please visit: http://www.medniva.com/intelearn/
About Duke-NUS Medical School
The Duke-NUS Medical School (Duke-NUS) was established in 2005 as a strategic collaboration between the Duke University School of Medicine, located in North Carolina, USA, and the National University of Singapore (NUS). Duke-NUS offers a graduate-entry, 4-year MD (Doctor of Medicine) training programme based on the unique Duke model of education, with one year dedicated to independent study and research projects of a basic science or clinical nature. Duke-NUS also offers MD/PhD and PhD programmes. Duke-NUS has five Signature Research Programmes: Cancer and Stem Cell Biology, Neuroscience and Behavioural Disorders, Emerging Infectious Diseases, Cardiovascular and Metabolic Disorders, and Health Services and Systems Research.
Duke-NUS and SingHealth have established a strategic partnership in academic medicine that will guide and promote the future of medicine, tapping on and combining the collective strengths of SingHealth's clinical expertise and Duke-NUS' biomedical sciences research and medical education capabilities.
For more information, please visit www.duke-nus.edu.sg
For media enquiries, please contact:
Edelman Public Relations Singapore
Ashley Lau
Tel: +65 6494 1578
Email: [email protected]
SOURCE MEDNIVA
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article